Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: BEAM.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Beam Therapeutics (BEAM) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$30

+21.9%

2031

5-Year

BUY

$72

+189.1%

Published batch insight

In Vivo Base Editing Platform Transitions Clinical Proof Into Commercial Dominance

High consensus confirms that proprietary in vivo base editing represents an unpriced technological paradigm shift over legacy CRISPR-Cas9 cutting. While annual cash burn requires disciplined financing, accelerated biomarker approval pathways and liquid balance-sheet reserves through mid-2029 position clinical execution to drive substantial enterprise re-rating.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), J.P. Morgan (Titan), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Ray Dalio (Strategist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Beam Therapeutics at the forecast anchor (2026-09-18): $28,908 in five years versus $13,892 for S&P 500 benchmark.

Beam Therapeutics · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Beam Therapeutics compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 24.95 USD1-year price return: +21.91%5-year price return: +189.08%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	25.88	+3.72%	+3.72%	Year-end tax-loss harvesting and elevated interest rates pressure pre-commercial biotechnology assets, but risto-cel filing preparations and mature clinical durability updates provide underlying support, stabilizing equity valuation near established balance-sheet asset floors.
Q1 2027	27.18	+5.05%	+8.96%	Regulatory momentum advances as the risto-cel filing enters formal review, while pivotal enrollment for lead in vivo programs accelerates, reassuring institutional investors and supporting modest equity accumulation despite persistent macroeconomic capital costs.
Q2 2027	28.29	+4.05%	+13.37%	Operating expenditures expand as late-stage clinical cohorts scale, prompting brief multiple consolidation. Cash reserves and initial partnership milestone revenues partially offset quarterly research outlays, keeping the trading range orderly.
Q3 2027	30.42	+7.53%	+21.91%	Interim biomarker disclosures across in vivo cohorts confirm sustained target engagement without serious hepatotoxicity. Clinical de-risking begins decoupling systemic base editing from cell-therapy peer headwinds, stimulating selective institutional accumulation.
Q4 2027	32.93	+8.25%	+31.96%	Anticipation and achievement of regulatory milestones for the lead hematology program validate human base editing fidelity. Valuation expands meaningfully as commercial readiness begins, despite market awareness of transplant conditioning bottlenecks.
Q1 2028	33.06	+0.42%	+32.52%	Early commercial rollout reveals logistical throughput limitations in autologous cell therapy, moderating immediate revenue expectations. Increased pre-launch expenditures trigger a temporary valuation consolidation following the initial approval rally.
Q2 2028	36.20	+9.48%	+45.08%	Pivotal biomarker readouts in alpha-1 antitrypsin deficiency demonstrate robust functional protein restoration, validating systemic in vivo editing efficacy. Strong clinical proof activates the agreed accelerated approval pathway, sparking substantial institutional accumulation.
Q3 2028	38.79	+7.17%	+55.48%	Accelerated approval biologics license submission formalizes commercialization timelines for the lead in vivo asset. Investor focus shifts toward scalable outpatient infusion economics, driving positive multi-quarter multiple expansion.
Q4 2028	41.38	+6.66%	+65.84%	Management executes a strategic financing or partnership transaction to fortify commercial balance-sheet reserves. Transient per-share dilution is tempered by the elimination of medium-term refinancing risk into pivotal regulatory decisions.
Q1 2029	44.04	+6.44%	+76.52%	Priority review progress and supportive regulatory engagement for in vivo base editing sustain market enthusiasm. Favorable macro financial conditions and stabilizing discount rates provide incremental valuation tailwinds.
Q2 2029	48.68	+10.53%	+95.11%	Regulatory approval of the lead in vivo genetic medicine marks a historic technological milestone, unlocking commercial rare-disease monopoly revenues. Institutional re-rating accelerates as high-margin systemic infusions reach diagnosed patient populations.
Q3 2029	50.50	+3.74%	+102.40%	Initial commercial distribution metrics confirm strong physician demand and supportive payer reimbursement. High product gross margins begin offsetting corporate research expenditures, cementing an inflection in operating cash flow trajectories.
Q4 2029	53.50	+5.95%	+114.45%	Ex-US commercial licensing partnerships inject non-dilutive milestone capital, extending liquidity runway well beyond previous horizons and permanently resolving lingering balance-sheet solvency concerns.
Q1 2030	55.12	+3.02%	+120.92%	Commercial revenue expansion continues across specialized centers, while follow-on metabolic clinical pipeline updates demonstrate platform repeatability, reinforcing durable competitive moats and sustaining steady upward valuation drift.
Q2 2030	58.46	+6.06%	+134.31%	International regulatory filings and expanding domestic market penetration broaden total addressable revenue. Operational overhead scales moderately, but growing commercial receipts absorb expenses, driving substantial operating leverage.
Q3 2030	60.34	+3.22%	+141.86%	Routine market consolidation and seasonal biopharma volume digestion induce modest consolidation. Pipeline advancements in second-generation conditioning platforms provide fundamental support, maintaining an elevated valuation baseline.
Q4 2030	63.84	+5.80%	+155.88%	Scaling commercial sales and expanding gross contribution margins narrow quarterly cash burn toward corporate breakeven. Fundamental healthcare allocators expand core equity stakes as commercial execution replaces speculative research milestones.
Q1 2031	66.33	+3.89%	+165.84%	Achieving initial operating cash-flow neutrality resets corporate risk perception. Predictable commercial revenue and non-genotoxic conditioning clinical progress drive institutional accumulation, reinforcing through-cycle valuation multiples.
Q2 2031	69.43	+4.68%	+178.28%	Label expansion initiatives and advancing Phase 2 readouts across secondary metabolic programs demonstrate sustainable pipeline rejuvenation, supporting compounding equity valuation gains.
Q3 2031	72.12	+3.88%	+189.08%	Terminal five-year realization establishes the enterprise as a profitable commercial genetic medicine leader. Durable high-margin sales and an unassailable base-editing patent fortress complete a multi-year valuation rerating.

The central investment thesis rests on an asymmetric operational transition from capital-intensive, transplant-constrained ex vivo cell engineering toward proprietary, high-margin in vivo base editing. By executing single-nucleotide transitions without inducing double-stranded DNA breaks, the platform evades chromosomal translocations and genotoxic p53 activation, securing superior therapeutic margins over legacy nucleases. Although the market anchors valuation to the sluggish commercialization of first-generation sickle cell therapies, lead asset BEAM-302 addresses alpha-1 antitrypsin deficiency as an off-the-shelf systemic infusion with FDA alignment on surrogate biomarker accelerated approval. With $1.2 billion in cash and debt commitments securing runway into mid-2029, clinical execution can bridge development into commercial cash flows before dilutive restructuring becomes existential.

Key insights

Direct hepatocyte transfection bypasses myeloablative conditioning, decoupling systemic in vivo genetic medicine from hospital transplant throughput bottlenecks.
Accelerated approval biomarker endpoints compress registrational review timelines by multi-year increments, significantly expanding discounted net present value.
Persistent annual free cash consumption of $370 million guarantees secondary equity dilution, moderating per-share equity realization across long horizons.

Deep Dive

Prevailing consensus treats the company as a speculative, cash-burning platform biotech burdened by elevated interest rates and sluggish gene therapy rollouts. Media commentary and sell-side notes heavily discount in vivo delivery prospects, anchoring on Casgevy's slow commercial adoption to dismiss sickle cell upside while assuming heavy clinical trial expenditures will inevitably force punishing shareholder dilution.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value due to an analytical misclassification that conflates ex vivo cell therapy friction with in vivo base-editing scalability. While consensus fixates on myeloablative conditioning bottlenecks in sickle cell disease, it overlooks that BEAM-302 operates as an outpatient systemic infusion with formal regulatory alignment on accelerated biomarker approval. This creates significant underpricing, as the market values the entire enterprise near net liquid assets while assigning negligible value to an uncontested multi-billion-dollar systemic liver monopoly.

Repricing catalyst

Definitive 12-month pivotal cohort biomarker readouts for BEAM-302, demonstrating functional serum protein restoration and toxic polymer clearance, represent the primary trigger. Expected between late 2027 and early 2028 alongside risto-cel regulatory review progress, observable biomarker durability will validate accelerated approval feasibility. This will compel institutional analysts to model near-term commercial cash flows rather than speculative science.

Published consensus context

Macro regime alignment

The prevailing monetary regime of four-percent benchmark policy rates and elevated long-term Treasury yields presents a distinct valuation headwind for long-duration biotechnology equities. High discount rates penalize pre-revenue cash flows. However, the company's $1.2 billion liquid buffer insulates clinical operations from restrictive credit markets, transforming sector liquidity contraction into a relative competitive moat against undercapitalized peers.

Published consensus context

Advisor disagreement

The primary analytical debate centers on the feasibility and timing of commercial cash flow inflection versus balance-sheet depletion. Bullish perspectives argue that FDA biomarker alignment on BEAM-302 enables accelerated commercial launch by 2028, unlocking high-margin rare-disease revenues that bridge the enterprise to operating self-sufficiency. Conversely, skeptical views emphasize that clinical cash combustion exceeding $370 million annually, combined with sluggish cell therapy adoption and tight monetary conditions, will necessitate dilutive equity offerings that reset per-share valuation. This disagreement will be definitively resolved by FDA acceptance of the accelerated approval filing package in 2027-2028 and initial commercial uptake metrics.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

In Vivo Systemic Base Editing Validation: Clinical progression of BEAM-302 directly validates systemic in vivo base editing via lipid nanoparticles in humans, concurrently correcting hepatic and pulmonary pathology in alpha-1 antitrypsin deficiency. By executing single-base transitions without double-strand DNA breaks, the platform achieves physiological protein restoration while avoiding chromosomal translocations, establishing superior safety and pricing power. Expected impact: +65%.
Surrogate Biomarker Accelerated Approval Pathway: Regulatory alignment with the FDA permitting accelerated approval based on 12-month circulating functional AAT biomarker thresholds significantly compresses clinical development timelines. Bypassing multi-year clinical lung-function decline trials pulls commercial launch forward, reducing cumulative trial expenditures and unlocking high-margin commercial revenue years ahead of traditional orphan-drug review pathways. Expected impact: +45%.
Fortress Balance Sheet Operational Runway: Holding $1.2 billion in liquid reserves alongside structured credit capacity provides operational runway extending into mid-2029. This financial insulation eliminates acute refinancing vulnerability during restrictive monetary cycles, enabling management to advance dual pivotal cohorts to commercial inflection without accepting predatory or distressed equity financing terms. Expected impact: +30%.
Foundational Base Editing Patent Architecture: Exclusive foundational intellectual property licenses covering adenosine and cytidine base editing establish an impenetrable legal moat against industry entrants. Global pharmaceutical conglomerates seeking non-cleaving genomic correction must license proprietary chemistry, generating substantial non-dilutive milestone inflows, co-development capital, and long-term tollbooth royalties that expand corporate operating leverage. Expected impact: +25%.

Top frictions and headwinds

Relentless Multi-Hundred-Million Cash Combustion: Operating losses exceeding $370 million annually reflect heavy clinical commitments across parallel pivotal trials and internal manufacturing infrastructure. Without recurring product revenues, continuous capital consumption steadily depletes liquid reserves, creating unavoidable equity dilution overhang as the corporate development runway approaches commercial launch windows. Expected impact: -30%.
Ex Vivo Conditioning Commercial Impasse: Autologous cell therapies like risto-cel face severe real-world adoption friction due to toxic myeloablative busulfan preconditioning, intensive apheresis requirements, and limited specialized transplant center bed capacity. Sluggish market penetration seen across commercialized gene therapies confirms near-term hematology revenues will ramp slowly, constraining early cash generation. Expected impact: -20%.
Restrictive High Hurdle Rate Valuation Compression: Federal Reserve monetary tightening and benchmark sovereign yields near five percent structurally elevate the cost of capital, penalizing pre-commercial biotechnology assets whose cash flows lie years in the future. High discount rates compress enterprise multiples, muting market appreciation despite positive clinical biomarker achievements. Expected impact: -18%.
Advanced LNP Scale-Up Manufacturing Complexity: Scaling cGMP manufacturing for systemic mRNA-lipid nanoparticle formulations introduces complex chemistry, manufacturing, and controls challenges. Stringent lot-release assays, cold-chain storage logistics, and specialized raw material procurement increase initial unit costs, dampening gross margins and introducing prospective regulatory audit risks during pivotal registration filings. Expected impact: -15%.

Tail risks

Pivotal In Vivo Hepatotoxicity Clinical Hold: Emergence of unexpected dose-limiting transaminitis, vector immunogenicity, or off-target deamination in expanded pivotal cohorts prompts an immediate FDA clinical hold on BEAM-302. Such a biological setback would invalidate the systemic in vivo delivery thesis, destroying platform credibility and stranding the business in lower-margin ex vivo niches. Probability: +20%. Expected impact: -55%.
Regulatory Rejection of Surrogate Biomarker Endpoints: Regulatory agencies reverse guidance and mandate five-year clinical pulmonary decline endpoints rather than circulating AAT restoration for commercial approval. Delaying commercialization into the 2030s would exhaust existing cash reserves before revenue inflection, forcing emergency dilutive equity issuance under punitive market conditions and permanently impairing per-share value. Probability: +25%. Expected impact: -42%.

Tail opportunities

First-In-Class Accelerated Approval Triumph: A rapid FDA priority review grants accelerated approval for BEAM-302 by 2028 based on definitive 52-week biomarker data, inaugurating the world's first commercial in vivo base editor. This historic regulatory de-risking establishes an uncontested commercial monopoly in severe AATD, driving rapid patient conversion, eliminating external financing requirements, and triggering massive institutional multiple expansion. Probability: +35%. Expected impact: +75%.
Non-Genotoxic Conditioning Platform Validation: Phase 1 clinical proof-of-concept for the ESCAPE platform demonstrates targeted antibody-mediated stem-cell depletion without toxic chemotherapy conditioning. Removing the busulfan barrier transforms ex vivo cell therapies into safe outpatient procedures, expanding the treatable sickle cell population tenfold and unlocking multi-billion-dollar biopharma licensing transactions across non-malignant hematology. Probability: +28%. Expected impact: +65%.

What to monitor

Thesis watchpoints

-- Confirmation: BEAM-302 pivotal cohort maintains serum total AAT normalization above 11 micromolar across treated patients through mid-2027.

Key insights

Deterioration: Emergence of grade 3 or higher liver transaminase toxicities in expanded cohorts triggers FDA protocol amendments before late-2027.
Reassessment: Total unrestricted liquid reserves drop below $600 million without non-dilutive licensing inflows by mid-2028, demanding immediate operational restructuring.

Company Financial Analysis

Beam Therapeutics Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The company's headline revenues resemble an irregular burst pattern rather than a traditional business. While trailing twelve-month revenues reached $156 million due to intermittent partnership payments, quarterly receipts plunged to just $490 thousand in mid-2026. This extreme swing occurs because the business has no approved commercial drugs on the market yet, relying entirely on sporadic upfront licensing checks from large pharmaceutical partners. Behind the headline numbers sits a steady clinical engine consuming cash. Trailing operating losses of $378 million and free cash flow burn of $373 million reflect intense development expenditures across parallel human trials. Until proprietary therapies secure regulatory approval and generate commercial sales, reported earnings will remain deeply negative, making clinical milestones far more informative than quarterly accounting profits.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 139.7M	USD -80M	USD -360M
2024	USD 63.5M	USD -376.7M	USD -356.2M
2023	USD 377.7M	USD -132.5M	USD -182.9M
2022	USD 60.9M	USD -289.1M	USD -26.4M
2021	USD 51.8M	USD -370.6M	USD -113.1M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Examining traditional profit margins today reveals the distorted economics of pre-commercial biotechnology. Operating margins registered at negative 275% in fiscal 2025, swinging alongside lumpy collaboration revenue recognition. While gross margins can appear deceptively high at 84% during milestone quarters, ongoing operational overhead ensures substantial net losses while treatments remain in clinical testing. These negative margins represent intentional developmental investments rather than flawed long-term unit economics. Once systemic in vivo therapies clear regulatory approvals, the underlying economics of precision genetic medicines are expected to yield commercial gross margins exceeding 80%. As commercial product sales scale, high unit profitability should rapidly absorb fixed platform overhead, driving significant operating margin expansion.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -383.7M	-274.6%	-57.2%
2024	USD -415.6M	-654.3%	-593.1%
2023	USD -176.5M	-46.7%	-35.1%
2022	USD -338.5M	-555.6%	-474.5%
2021	USD -392.5M	-757.0%	-714.9%

Balance sheet and leverage

AI Review

The corporate balance sheet serves as a vital strategic shield against difficult financial markets. Holding $1.2 billion in liquid cash, cash equivalents, and marketable securities as of mid-2026, the company maintains an exceptional current ratio exceeding 13.0. A conservative debt structure featuring a debt-to-equity ratio of 0.24 protects the business from immediate credit distress or predatory debt covenants. However, headline liquidity must be balanced against ongoing cash burn. Annual operating cash consumption of roughly $370 million gives the business approximately three years of operational autonomy, extending funding into mid-2029. This multi-year cushion enables management to complete critical pivotal clinical trials and seek regulatory approvals without resorting to emergency stock offerings at depressed market prices.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 293.9M	USD 1.2B	USD 1.1M net cash	13.09x
2024	USD 161.4M	USD 850.7M	USD 120.5M net cash	4.82x
2023	USD 172.7M	USD 1.2B	USD 263.2M net cash	5.89x
2022	USD 179M	USD 1.1B	USD 53.8M net cash	4.89x
2021	USD 147.6M	USD 965.6M	USD 412.4M net cash	5.96x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Physical capital spending on brick-and-mortar facilities has moderated substantially, dropping to roughly 11% of recognized revenues after heavy historical investments in internal manufacturing. Management completed construction of its specialized North Carolina cGMP production plant early, which now insulates the pipeline from third-party manufacturing bottlenecks without requiring major new facility construction outlays during current high-interest periods. Instead, true investment intensity is concentrated in scientific human capital and clinical trial execution. Annual research and development expenditures consistently absorb approximately $400 million, financing patient enrollment, lipid nanoparticle formulation, and rigorous safety bioanalytics. This strategic allocation preserves physical capital while channeling corporate resources directly into building valuable, patent-protected clinical assets.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 14.9M	USD 409.6M
2024	USD 8.9M	USD 367.6M
2023	USD 33.7M	USD 437.4M
2022	USD 49M	USD 311.6M
2021	USD 46.8M	USD 387.1M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	174	+22.9%	Not available	ORIGINAL
5Y	BUY	224	+206%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	23.7	25.91	27.45	14
+6M	March 18, 2027	24.41	27.29	30.18	14
+9M	June 18, 2027	25.64	28.38	31.99	14
+1Y	September 18, 2027	26.15	30.67	37.75	14
+15M	December 18, 2027	27.72	33.2	40.12	14
+18M	March 18, 2028	26.61	33.09	42.12	14
+21M	June 18, 2028	27.41	36.47	45.91	14
+2Y	September 18, 2028	28.78	39.03	48.67	14
+27M	December 18, 2028	29.89	41.85	57.43	14
+30M	March 18, 2029	29.59	44.83	61.66	14
+33M	June 18, 2029	30.77	49.65	75.23	14
+3Y	September 18, 2029	31.7	51.86	81.25	14
+39M	December 18, 2029	32.96	55.25	90.18	14
+42M	March 18, 2030	33.62	56.66	86.58	14
+45M	June 18, 2030	34.63	60.15	94.37	14
+4Y	September 18, 2030	37.06	62.81	105.69	14
+51M	December 18, 2030	38.17	66.78	114.15	14
+54M	March 18, 2031	38.93	69.89	125.56	14
+57M	June 18, 2031	40.49	73.26	134.35	14
+5Y	September 18, 2031	41.3	76.35	142.41	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The evidentiary consensus establishes a profound structural bifurcation: while first-generation ex vivo cell therapy faces severe commercial constraints due to toxic conditioning and transplant center bottlenecks, systemic in vivo base editing demonstrates transformative clinical efficacy. Reports rigorously grounded in primary SEC filings, audited liquidity metrics, and verified clinical congress readouts receive the highest weightings. These inputs correctly account for an annual cash burn of approximately $370 million, floating-rate debt obligations, and inevitable equity dilution schedules that cap per-share compounding. Conversely, reports projecting frictionless multi-billion-dollar commercial ramps or unmitigated multiple expansion are downweighted for underestimating macro duration penalties under elevated policy rates. The credible contrarian case warns that surrogate biomarker rejection or emergent lipid nanoparticle hepatotoxicity could trigger regulatory holds and liquidity exhaustion. Relative weights prioritize analytical discipline that balances definitive in vivo biomarker de-risking against unavoidable equity dilution and operational capital intensity through 2029.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.0/100

Exceptional evidentiary grounding utilizing audited SEC filings, ERS congress clinical data, and peer commercial benchmarks. Rigorously accounts for per-share equity dilution schedules, floating-rate debt drag, and real-world cell therapy capacity constraints, establishing superior causal credibility.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight9.0/100

Offers rigorous balance-sheet scrutiny, anchoring on cash-backed downside asset protection and replacement cost of intellectual property. Recognizes the structural inflection from ex vivo cell therapy to systemic in vivo delivery, though assumes slightly accelerated commercial uptake schedules in alpha-1 antitrypsin deficiency.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight9.0/100

Anchors on rigorous fundamental valuation, contrasting net liquid assets per share against enterprise replacement costs. Cites verified clinical trial disclosures while properly penalizing long-duration cash flows for cost of capital and clinical development delays.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight8.0/100

Combines acute forensic attention to credit facility covenants and cash burn with realistic appraisal of surrogate biomarker endpoints. Accurately identifies the accelerated approval mechanism as the critical valuation bridge, balancing regulatory upside against severe clinical execution risks.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight8.0/100

Delivers robust multi-dimensional analysis linking surrogate biomarker readouts to accelerated biologics licensing timelines. Integrates primary SEC disclosures and liquidity runway data effectively, providing a balanced synthesis between scientific breakthrough potential and persistent macroeconomic multiple compression.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight8.0/100

Presents strong macroeconomic regime framing, mapping the impact of four-percent benchmark rates onto long-duration biological assets. Successfully demonstrates how balance-sheet liquidity insulates clinical trials from external credit freezes, though slightly understates unit-level cell therapy commercial friction.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight8.0/100

Provides sharp strategic analysis of regulatory alignment on surrogate endpoints and institutional pricing friction. Accurately maps the transition from ex vivo transplantation bottlenecks to outpatient in vivo infusions, backed by solid capital runway verification.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight7.0/100

Provides a measured framework balancing clinical de-risking against ongoing operating cash burn. Properly highlights the genotoxic safety advantages of single-base transition chemistry over double-strand breaks while accurately forecasting that secondary equity offerings will temper long-term per-share compounding.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight7.0/100

Exhibits strong discipline regarding negative owner earnings, capital allocation, and valuation sensitivity to high risk-free interest rates. Correctly identifies the non-genotoxic conditioning platform as an unpriced competitive option, though somewhat understates the near-term clinical velocity of the in vivo pipeline.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight6.0/100

Thoroughly details registrational timeline dynamics across lead clinical programs, supported by primary medical disclosures. However, it overweights peak sovereign market potential while minimizing commercial friction in cell therapy distribution and persistent discount-rate headwinds in valuation models.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight6.0/100

Articulates the civilizational shift toward precision base editing with strong biological insight, though exhibits minor narrative optimism regarding global commercialization pacing. Demonstrates consistent reasoning regarding cash runway insulation and regulatory milestone catalysts.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight5.0/100

Presents sound analysis of in vivo base-editing differentiation versus Cas9 cutting, but incorporates aggressive long-term valuation compounding without adequate modeling of near-term dilution mechanics. Qualitative arguments are causally coherent but lack balanced balance-sheet sensitivity checks relative to more disciplined financial inputs.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight5.0/100

Captures the technological leap of direct hepatocyte transfection via lipid nanoparticles, yet applies overly enthusiastic adoption timelines and terminal multiples. Underplays the real-world friction of clinical trial enrollment and specialized hospital administration logistics during launch phases.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight3.0/100

Provides thorough financial analysis, but assigns disproportionately high probability to standalone event impacts and includes speculative robotics claims. Its resulting return checkpoints diverge materially from the balanced consensus path, warranting a lower relative weighting.

Skip to references

Research Provenance

References & Context

This Beam Therapeutics consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 84 deduplicated sources retained for this batch.

And 69 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2017-12-31–2025-12-31, 9 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.